learningcurve2020,
More like NICE wants everyone ready for a big change and that includes financial preparedness, supply chain preparedness and NHS preparedness for patient use of set asides, transition to regular reimbursement and all systems go for planned ramp up all the way around which NWBO has been working on with Flaskworks, digitization of processes, final choice of Edens unit, space prepared for its use ie modified B class clean room preparations and Advent’s expansion into leukapheresis center space.
Once the projects are all set in motion at the right time, NWBO and Advent will be ready for the transition and NHS as well. This will help expedite all NICE decision making after facilitating it being coordinated with increasing quality life years that are still accumulating from L patients when NWBO sends their evidence package to them. Sure seems like there has been time being bought for funding as the serious increase in budgeting for NHS funding came last year which is when NHS put murcidencel on its funding list for high priced treatments. Getting this set up and running is just as important to an efficient start for patients as MAA approval itself is when demand is expected to come fast from doctors and patients expecting approval. I would expect that GBM tumors are being banked by now by Dr. Ashkan’s patients and if so, revenue from this should be growing at Advent. I would also think that leukapheresis centers might be preparing for an increase in operations right before approval which should be palpable with regard to employee observations. These are finger on the pulse type of indicators. I wonder if any of the recent buying near $.30 is from those who have their finger on the pulse. May will be here soon enough; ). Best wishes.
Market Data 
Markets 
AI
